Cargando…

Induction of Remission in Pediatric Crohn’s Disease Patients Assessed by the Mucosal Inflammation Noninvasive Index

Mucosal healing (MH) is the main therapeutic goal of Crohn’s disease (CD). The Mucosal Inflammation Noninvasive Index (MINI) appears to be a promising tool for distinguishing MH from its inflammation. This study aims to evaluate MINI in monitoring remissions induced by exclusive enteral nutrition (E...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herman, Roma, Dumnicka, Paulina, Pieczarkowski, Stanisław, Fyderek, Krzysztof
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8658516/ https://www.ncbi.nlm.nih.gov/pubmed/34884315 http://dx.doi.org/10.3390/jcm10235613

Ejemplares similares

Clinical usefulness of the Mucosal Inflammation Noninvasive Index in newly diagnosed paediatric Crohn’s disease patients
por: Herman, Roma B., et al.
Publicado: (2021)

A review of magnetic resonance enterography based Crohn’s disease activity indices in paediatric patients
por: Herman, Roma B., et al.
Publicado: (2022)

Plasma elafin, cathelicidin, and α-defensins are increased in paediatric inflammatory Crohn’s disease and reflect disease location
por: Wędrychowicz, Andrzej, et al.
Publicado: (2021)

Differences in the intestinal microbiome of healthy children and patients with newly diagnosed Crohn’s disease
por: Kowalska-Duplaga, Kinga, et al.
Publicado: (2019)

Clinical value of serum eosinophilic cationic protein assessment in children with inflammatory bowel disease
por: Wędrychowicz, Andrzej, et al.
Publicado: (2013)

A New Way to Assess the Trajectory of Remission in Crohn Disease: Correlating Drug Levels With a Noninvasive Blood Biomarker of Mucosal Remission
por: Gremida, Anas, et al.
Publicado: (2021)

Diagnostic Value of Fecal Calprotectin (S100 A8/A9) Test in Children with Chronic Abdominal Pain
por: Pieczarkowski, Stanisław, et al.
Publicado: (2016)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

Infliximab for medical induction of remission in Crohn's disease
por: Gordon, Morris, et al.
Publicado: (2023)

Infliximab Therapy Could Decrease the Risk of the Development of Thyroid Disorders in Pediatric Patients With Crohn's Disease
por: Furtak, Aleksandra, et al.
Publicado: (2020)

Effectiveness of Crohn’s Disease Exclusion Diet for Induction of Remission in Crohn’s Disease Adult Patients
por: Szczubełek, Martyna, et al.
Publicado: (2021)

Outcomes of Pediatric Patients with Crohn's Disease Received Infliximab or Exclusive Enteral Nutrition during Induction Remission
por: Lv, Yao, et al.
Publicado: (2022)

Structural robustness of the gut mucosal microbiota is associated with Crohn's disease remission after surgery
por: Mondot, S, et al.
Publicado: (2016)

Potential Utility of Therapeutic Drug Monitoring of Adalimumab in Predicting Short-Term Mucosal Healing and Histologic Remission in Pediatric Crohn's Disease Patients
por: Choi, So Yoon, et al.
Publicado: (2020)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2022)

Fecal Calprotectin Assay at an Early Stage of Treatment Can Be Used as a Surrogate Marker to Predict Clinical Remission and Mucosal Healing in Pediatric Crohn’s Disease
por: Lee, Yeoun Joo, et al.
Publicado: (2022)

Usefulness of the capsule endoscopy Crohn's disease activity index in assessing the necessity of early additional treatment in patients with Crohn's disease in clinical remission
por: Miyazu, Takahiro, et al.
Publicado: (2021)

Serum Ustekinumab Concentrations Are Associated With Remission in Crohn’s Disease Defined by a Serum-Based Endoscopic Healing Index
por: Walshe, Margaret, et al.
Publicado: (2021)

Dependence of Colonization of the Large Intestine by Candida on the Treatment of Crohn’s Disease
por: KOWALSKA-DUPLAGA, KINGA, et al.
Publicado: (2019)

Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission
por: Lin, Xiaoqin, et al.
Publicado: (2020)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
por: Wu, Kai-Chun, et al.
Publicado: (2016)

Budesonide for the Induction and Maintenance of Remission in Crohn’s Disease: Systematic Review and Meta-Analysis for the Cochrane Collaboration
por: Kuenzig, M Ellen, et al.
Publicado: (2018)

Crohn’s disease in remission or simply smouldering?
por: Gaya, Daniel R.
Publicado: (2015)

Dysbiosis of Gut Fungal Microbiota is Associated With Mucosal Inflammation in Crohn’s Disease
por: Li, Qiurong, et al.
Publicado: (2014)

Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab
por: Scarozza, Patrizio, et al.
Publicado: (2020)

Oral exclusive enteral nutrition for induction of clinical remission, mucosal healing, and improvement of nutritional status and growth velocity in children with active Crohn’s disease – a prospective multicentre trial
por: Matuszczyk, Małgorzata, et al.
Publicado: (2021)

Sustained Diet-Induced Remission in Pediatric Crohn’s Disease Is Associated With Kynurenine and Serotonin Pathways
por: Ghiboub, Mohammed, et al.
Publicado: (2023)

Food for Thought: Remission of Perianal Pediatric Crohn’s Disease on Specific Carbohydrate Diet Monotherapy
por: Simon, David, et al.
Publicado: (2023)

Imaging Modalities for the Noninvasive Assessment of Fibrosis in Crohn's Disease
por: Stasi, Cristina, et al.
Publicado: (2012)

Thalidomide induces clinical remission and mucosal healing in adults with active Crohn’s disease: a prospective open-label study
por: He, Yao, et al.
Publicado: (2017)

Correction to: Normalization of C-Reactive Protein Predicts Better Outcome in Patients With Crohn's Disease With Mucosal Healing and Deep Remission
por: Lin, Xiaoqing, et al.
Publicado: (2020)

Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis
por: Hashash, Jana G., et al.
Publicado: (2021)

The Role of Partial Enteral Nutrition for Induction of Remission in Crohn’s Disease: A Systematic Review of Controlled Trials
por: González-Torres, Lucía, et al.
Publicado: (2022)

Association between Fecal Calprotectin and Mucosal Healing in Pediatric Patients with Crohn’s Disease Who Have Achieved Sustained Clinical Remission with Anti-Tumor Necrosis Factor Agents
por: Lee, Yoo Min, et al.
Publicado: (2022)

Macrocytosis during sunitinib treatment predicts progression-free survival in patients with metastatic renal cell carcinoma
por: Kucharz, Jakub, et al.
Publicado: (2016)

Inflammation-Induced Mucosal KYNU Expression Identifies Human Ileal Crohn’s Disease
por: Huhn, Meik, et al.
Publicado: (2020)

Blockage of bacterial FimH prevents mucosal inflammation associated with Crohn’s disease
por: Chevalier, Grégoire, et al.
Publicado: (2021)

Noninvasive Targeted Crohn Disease Management by Combining Endoscopic Healing Index and Therapeutic Drug Monitoring
por: Hemperly, Amy, et al.
Publicado: (2021)

Noninvasive biomarkers as surrogate predictors of clinical and endoscopic remission after infliximab induction in patients with refractory ulcerative colitis
por: Hassan, Elham A., et al.
Publicado: (2017)

Exclusive Enteral Nutrition Induces Remission in Pediatric Crohn's Disease via Modulation of the Gut Microbiota
por: Gong, Dawei, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ecmu4lqfl4cp4kf9eoh3pvb54v